Clinical Trial Update: STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS [Phase 2]

View source ↗

Summary

Phase 2 STIMULUS MDS-US trial evaluating Sabatolimab added to hypomethylating agents in higher-risk myelodysplastic syndrome has been terminated, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Sabatolimab (sabatolimab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED | Results posted: 2025-07-31